MHC-peptide specificity and T-cell epitope mapping: where immunotherapy starts

Trends in Molecular Medicine

Volumn 12, Issue 10, 2006, Pages 465-472

  Provenzano, Maurizio ^a   Panelli, Monica C ^b   Mocellin, Simone ^c   Bracci, Laura ^a   Sais, Giovanni ^a   Stroncek, David F ^b   Spagnoli, Giulio C ^a   Marincola, Francesco M ^b  

^a UNIVERSITY OF BASEL   (Switzerland)

^b Clinical Center   (United States)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANYLALANYLGLYCYLISOLEUCYLGLYCYLISOLEUCYLLEUCYLTHREONYLVALINE; EPITOPE; HLA ANTIGEN CLASS 1; ISOLEUCYLMETHIONYLASPARTYLGLUTAMINYLVALYLPROLYLPHENYLALANYLSERYLVALINE; ISOLEUCYLTHREONYLASPARTYLGLUTAMINYLVALYLPROLYLPHENYLALANYLSERYLVALINE; LEUCYLALANYLGLYCYLISOLEUCYLGLYCYLISOLEUCYLLEUCYLTHREONYLVALINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEPTIDE; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIGEN DETECTION; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLONAL ANERGY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; EPITOPE MAPPING; FLOW CYTOMETRY; HLA SYSTEM; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MELANOMA; MEMORY T LYMPHOCYTE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE ACTIVATION; VACCINATION;

ANIMALS; ANTIGEN PRESENTATION; EPITOPE MAPPING; EPITOPES, T-LYMPHOCYTE; HLA ANTIGENS; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; MODELS, BIOLOGICAL; PEPTIDES; POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SUBSTRATE SPECIFICITY;

EID: 33748980437     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2006.08.008     Document Type: Article

References (74)

1. Kondo E., et al. Identification of novel CTL epitopes of CMV-pp65 presented by a variety of HLA alleles. Blood 103 (2004) 630-638
2. Gandhi M.K., and Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect. Dis. 4 (2004) 725-738
3. Trivedi D., et al. Generation of CMV-specific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy. Blood 105 (2005) 2793-2801
4. Keever-Taylor C.A., et al. Cytomegalovirus-specific cytolytic T-cell lines and clones generated against adenovirus-pp65-infected dendritic cells. Biol. Blood Marrow Transplant. 7 (2001) 247-256
5. Foss F.M. Immunologic mechanisms of antitumor activity. Semin. Oncol. 29 (2002) 5-11
6. + T-cell responses cannot be predicted by major histocompatibility complex class I haplotype. J. Virol. 74 (2000) 9144-9151
7. + T cell responses. Hum. Gene Ther. 16 (2005) 348-360
8. Cavazza A., et al. Hydrolysis of the tumor-associated antigen epitope gp100(280-288) by membrane-associated and soluble enzymes expressed by immature and mature dendritic cells. Clin. Immunol. 111 (2004) 252-261
9. Rosenberg S.A., et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4 (1998) 321-327
10. + T cells with enhanced functional characteristics: implication for more effective immunotherapy. Cancer Res. 59 (1999) 301-306
11. Brinckerhoff L.H., et al. Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: implications for peptide vaccines. Int. J. Cancer 83 (1999) 326-334
12. Hanada K., et al. Immune recognition of a human renal cancer antigen through post-translational protein splicing. Nature 427 (2004) 252-256
13. Vigneron N., et al. An antigenic peptide produced by peptide splicing in the proteasome. Science 304 (2004) 587-590
14. Rammensee H., et al. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50 (1999) 213-219
15. Zhou M., et al. Screening and identification of severe acute respiratory syndrome-associated coronavirus-specific CTL epitopes. J. Immunol. 177 (2006) 2138-2145
16. Brodsky F.M., et al. Antigen processing and presentation. Tissue Antigens 47 (1996) 464-471
17. Kloetzel P.M., and Ossendorp F. Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. Curr. Opin. Immunol. 16 (2004) 76-81
18. van Hall T., et al. Differential influence on cytotoxic T lymphocyte epitope presentation by controlled expression of either proteasome immunosubunits or PA28. J. Exp. Med. 192 (2000) 483-494
19. Peters B., et al. Identifying MHC class I epitopes by predicting the TAP transport efficiency of epitope precursors. J. Immunol. 171 (2003) 1741-1749
20. Seliger B., et al. Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation. Int. J. Cancer 118 (2006) 129-138
21. Brouwenstijn N., et al. MHC class I molecules can direct proteolytic cleavage of antigenic precursors in the endoplasmic reticulum. Immunity 15 (2001) 95-104
22. Bhasin M., and Raghava G.P. Pcleavage: an SVM based method for prediction of constitutive proteasome and immunoproteasome cleavage sites in antigenic sequences. Nucleic Acids Res. 33 (2005) W202-W207
23. Hakenberg J., et al. MAPPP: MHC class I antigenic peptide processing prediction. Appl. Bioinformatics 2 (2003) 155-158
24. Nagorsen D., et al. Proteosomal cleavage does not determine immunogenicity of gp100-derived peptides gp100 209-217 and gp100 209-217T210M. Cancer Immunol. Immunother. 53 (2004) 817-824
25. Sette A., and Sidney J. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 50 (1999) 201-212
26. Takedatsu H., et al. Identification of peptide vaccine candidates sharing among HLA-A3+, -A11+, -A31+, and -A33+ cancer patients. Clin. Cancer Res. 10 (2004) 1112-1120
27. Thimme R., et al. Degenerate immunogenicity of an HLA-A2-restricted hepatitis B virus nucleocapsid cytotoxic T-lymphocyte epitope that is also presented by HLA-B51. J. Virol. 75 (2001) 3984-3987
28. Rudolf M.P., et al. Human T-cell responses to HLA-A-restricted high binding affinity peptides of human papillomavirus type 18 proteins E6 and E7. Clin. Cancer Res. 7 (2001) 788s-795s
29. Velders M.P., et al. Human T cell responses to endogenously presented HLA-A*0201 restricted peptides of Simian virus 40 large T antigen. J. Cell. Biochem. 82 (2001) 155-162
30. + T cells. Blood 101 (2003) 1460-1468
31. Rivoltini L., et al. Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells. J. Immunol. 171 (2003) 3467-3474
32. Diamond D.J., et al. Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood 90 (1997) 1751-1767
33. Khattab B.A., et al. Three T-cell epitopes within the C-terminal 265 amino acids of the matrix protein pp65 of human cytomegalovirus recognized by human lymphocytes. J. Med. Virol. 52 (1997) 68-76
34. Panelli M.C., et al. A tumor-infiltrating lymphocyte from a melanoma metastasis with decreased expression of melanoma differentiation antigens recognizes MAGE-12. J. Immunol. 164 (2000) 4382-4392
35. Britten C.M., et al. Identification of T cell epitopes by the use of rapidly generated mRNA fragments. J. Immunol. Methods 299 (2005) 165-175
36. +-mediated CMV-specific T cell responses. Mol. Ther. 13 (2006) 280-288
37. + cytotoxic T cells from human peripheral blood cells. Hum. Immunol. 65 (2004) 514-522
38. Zajac P., et al. Enhanced generation of cytotoxic T lymphocytes using recombinant vaccinia virus expressing human tumor-associated antigens and B7 costimulatory molecules. Cancer Res. 58 (1998) 4567-4571
39. Scheibenbogen C., et al. Identification of known and novel immunogenic T-cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL-2-based treatment. Int. J. Cancer 98 (2002) 409-414
40. Zhang, Y. et al. (2004) Screening of dominant epitopes of antigens related to antibodies in the sera of patients with nasopharyngeal carcinoma. Ai Zheng 23, 999-1004.
41. + T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay. Blood 98 (2001) 1872-1881
42. Pero S.C., et al. Identification of a small peptide that inhibits the phosphorylation of ErbB2 and proliferation of ErbB2 overexpressing breast cancer cells. Int. J. Cancer 111 (2004) 951-960
43. Kern F., et al. T-cell epitope mapping by flow cytometry. Nat. Med. 4 (1998) 975-978
44. Straathof K.C., et al. Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma. J. Immunol. 175 (2005) 4137-4147
45. Parker K.C., et al. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J. Immunol. 152 (1994) 163-175
46. Stordeur P., et al. Immune monitoring in whole blood using real-time PCR. J. Immunol. Methods 276 (2003) 69-77
47. Stordeur P., et al. Analysis of spontaneous mRNA cytokine production in peripheral blood. J. Immunol. Methods 261 (2002) 195-197
48. Kammula U.S., et al. Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination. J. Natl. Cancer Inst. 92 (2000) 1336-1344
49. Ohnmacht G.A., et al. Short-term kinetics of tumor antigen expression in response to vaccination. J. Immunol. 167 (2001) 1809-1820
50. Mocellin S., et al. Induction of endothelial nitric oxide synthase expression by melanoma sensitizes endothelial cells to tumor necrosis factor-driven cytotoxicity. Clin. Cancer Res. 10 (2004) 6879-6886
51. Mocellin S., et al. Quantitative real-time PCR: a powerful ally in cancer research. Trends Mol. Med. 9 (2003) 189-195
52. Panelli M.C., et al. The role of quantitative PCR for the immune monitoring of cancer patients. Expert Opin. Biol. Ther. 2 (2002) 557-564
53. Provenzano M., et al. The usefulness of quantitative real-time PCR in immunogenetics. ASHI Quarterly 3 (2001) 89-91
54. Lotze M.T., et al. Workshop on cancer biometrics: identifying biomarkers and surrogates of cancer in patients: a meeting held at the Masur Auditorium, National Institutes of Health. J. Immunother. 28 (2005) 79-119
55. Provenzano M., et al. Identification of immune dominant cytomegalovirus epitopes using quantitative real-time polymerase chain reactions to measure interferon-γ production by peptide-stimulated peripheral blood mononuclear cells. J. Immunother. 25 (2002) 342-351
56. Provenzano M., et al. Ex vivo screening for immunodominant viral epitopes by quantitative real time polymerase chain reaction (qRT-PCR). J. Transl. Med. 1 (2003) 12
57. Kammula U.S., et al. Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. J. Immunol. 163 (1999) 6867-6875
58. Ghei M., et al. Analysis of memory T lymphocyte activity following stimulation with overlapping HLA-A*2402, A*0101 and Cw*0402 restricted CMV pp65 peptides. J. Transl. Med. 3 (2005) 23
59. Ellis J.M., et al. Frequencies of HLA-A2 alleles in five U.S. population groups. Predominance of A*02011 and identification of HLA-A*0231. Hum. Immunol. 61 (2000) 334-340
60. Ressing M.E., et al. Differential binding of viral peptides to HLA-A2 alleles. Implications for human papillomavirus type 16 E7 peptide-based vaccination against cervical carcinoma. Eur. J. Immunol. 29 (1999) 1292-1303
61. + T-cell response in a Northern Chinese population. Tissue Antigens 62 (2003) 285-295
62. Bettinotti M.P., et al. Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy. J. Immunol. 161 (1998) 877-889
63. Rivoltini L., et al. Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy. J. Immunol. 156 (1996) 3882-3891
64. Provenzano M., et al. Comprehensive epitope mapping of the Epstein-Barr virus latent membrane protein-2 in ethically diverse populations. J. Immunother. 28 (2005) 617
65. + T cells in subjects bearing either HLA-A*2402 or A*0101 allele. Transfusion 43 (2003) 1567-1574
66. + T-lymphocyte subsets using quantitative real-time PCR. Scand. J. Immunol. 58 (2003) 601-606
67. Mocellin S., et al. Use of quantitative real-time PCR to determine immune cell density and cytokine gene profile in the tumor microenvironment. J. Immunol. Methods 280 (2003) 1-11
68. + T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood 102 (2003) 2892-2900
69. Dudley M.E., et al. Adoptive cell tranfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23 (2005) 2346-2357
70. + T cells. J. Immunol. 168 (2002) 5933-5942
71. Ito D., et al. Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4 mAb. J. Immunol. 164 (2000) 1230-1235
72. Zajac P., et al. Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients. Hum. Gene Ther. 14 (2003) 1497-1510
73. Berzofsky J.A., et al. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J. Clin. Invest. 113 (2004) 1515-1525
74. + CMV-specific cytotoxic T lymphocytes. Exp. Hematol. 34 (2006) 296-307